Christoph H. Westphal

Christoph H. Westphal is a declared insider at 5 companies (chief executive); the most frequent names are Sirtris Pharmaceuticals, Inc., Salarius Pharmaceuticals, Inc. and Verastem, Inc. We count 285 filings; the first trade dates from 29 May 2007 and the latest from 20 July 2021.

Market trades split into 96 purchases (€15.0M) and 114 sales (€3.0M). Purchases outweigh sales by €12.0M. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Besides market trades, the filings include 20 share grants and 2 option exercises. In 2021 alone, the filings show 1 purchase and no sales.

A typical purchase (the median) is worth €19k. On 12 out of 45 purchases, another insider of the same company was buying within the same 30 days. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase. Ninety days after publication, 13 purchases show a median change of +25.6%, with the price up in 77% of them. This is a record of the past, not a forecast.

The newest entry dates from 22 July 2021: an open-market purchase of €1.7M, in TScan Therapeutics, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. The legal deadline for a Form 4 is two business days after the transaction. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.